| Exscientia–Open Philanthropy: grant, 202312– grant $2.3m for research in host interferon response as therapeutic approach for pandemic influenza |
2023-12-05 |
| Freeline Therapeutics–Syncona: credit, 202311–202411 secured convertible loan note up to $15m with 12% interest + conversion price of $6.5/ADS |
2023-11-22 |
| Freeline Therapeutics–Syncona: investment, 202311– acquisition all remaining shares $6.5/ADS in going-private valuing entire issued capital at $28.3m |
2023-11-22 |
| Quotient Therapeutics–Flagship Pioneering: investment, 202311 Quotient Tx unveiled with initial $50m commitment from Flagship Pioneering |
2023-11-21 |
| T-Therapeutics–SEVERAL: investment, 202311 financing round Series A £48m |
2023-11-15 |
| Glox Therapeutics–SEVERAL: investment, 202311 seed financing round £4.3m led by BIVF + Scottish Enterprise |
2023-11-14 |
| ViaNautis Bio–4BIO Ventures: investment, 202311 financing round Series A totalling $25m incl co-lead investor 4BIO Capital |
2023-11-13 |
| ViaNautis Bio–BGF: investment, 202311 financing round Series A totalling $25m incl co-lead investor BGF |
2023-11-13 |
| ViaNautis Bio–Cystic Fibrosis Foundation: investment, 202311 financing round Series A totalling $25m incl co-investor Cystic Fibrosis Foundation |
2023-11-13 |
| ViaNautis Bio–Meltwind: investment, 202311 financing round Series A totalling $25m incl exisitng + co-investor Meltwind |
2023-11-13 |
| ViaNautis Bio–o2h: investment, 202311 financing round Series A totalling $25m incl exisitng + co-investor O2H |
2023-11-13 |
| ViaNautis Bio–Origin Capital: investment, 202311 financing round Series A totalling $25m incl exisitng + co-investor Origin Capital |
2023-11-13 |
| ViaNautis Bio–SEVERAL: investment, 202311 financing round Series A $25m led by 4BIO Capital + BGF + UCB Ventures |
2023-11-13 |
| ViaNautis Bio–UCB: investment, 202311 financing round Series A totalling $25m incl co-lead investor UCB Ventures |
2023-11-13 |
| Memo Therapeutics–SEVERAL: investment, 202311 financing round Series C CHF25m led by Pureos Bioventures to complete US phase 2 study with AntiBKV |
2023-11-02 |
| MeiraGTx–Sanofi: investment, 202310 strategic investment $30m with 4m ordinary shares at $7.5/share incl right of first negotation for some assets |
2023-10-30 |
| AstraZeneca–Nanoform: drug delivery technology, 202310– license ww to Starmap Online |
2023-10-23 |
| GSK–Hansoh Pharmaceutical: antibody-drug conjugates, 202310– license ww excl Greater China to HS-20089 $85m upfront + $1.485b milestones + royalties |
2023-10-20 |
| Oxford Nanopore–Mérieux: investment, 202310 investment £69.1m purchase of 29m ordinary shares at £2.38/share by bioMérieux |
2023-10-19 |
| SpliceBio–Optimum Strategic Communications: public relations, 202310 service existent by Optimum |
2023-10-17 |
| AstronauTx–Optimum Strategic Communications: public relations, 202310 service existent by Optimum |
2023-10-09 |
| AstronauTx–SEVERAL: investment, 202310 financing round Series A ¯£48m led by Novartis Venture Fund |
2023-10-09 |
| United Kingdom (govt)–Siemens: PET/CT scanner, 202310–202304 supply 2 Biograph Vision Quadra PET/CT scanners by Siemens Healthineers to NPIP |
2023-10-05 |
| Mogrify–SEVERAL: investment, 202310 financing round Series A extension $10m bringing total Series A to $46m led by Astellas VM & Parkwalk Advisors |
2023-10-02 |
| Refeyn–Alto Marketing: public relations, 202310 service existent by Alto Marketing Ltd |
2023-10-02 |
| Laverock Therapeutics–Calculus Capital: investment, 202309 seed financing round totalling £13.5m incl lead investor Calculus Capital |
2023-09-28 |
| Laverock Therapeutics–Lilly: investment, 202309 seed financing round totalling £13.5m incl co-investor Eli Lilly |
2023-09-28 |
| Laverock Therapeutics–Mattioli Woods: investment, 202309 seed financing round totalling £13.5m incl co-investor Maven Capital Partners |
2023-09-28 |
| Laverock Therapeutics–Mercia: investment, 202309 seed financing round totalling £13.5m incl co-investor Mercia Ventures |
2023-09-28 |
| Laverock Therapeutics–SEVERAL: investment, 202309 seed financing round expansion to £13.5m led by Calculus Capital |
2023-09-28 |
| 4SC–Optimum Strategic Communications: public relations, 202309 service existent by Optimum |
2023-09-27 |
| BioProtect–MVM: investment, 202309 financing round totalling $28m incl new + lead investor MVM Partners |
2023-09-27 |
| BioProtect–SEVERAL: investment, 202309 financing round $28m led by MVM Partners |
2023-09-27 |
| Crucible Therapeutics–Argobio: investment, 202309 financing round totalling £5m incl investor Argobio Studio |
2023-09-25 |
| Crucible Therapeutics–Northern Gritstone: investment, 202309 financing round totalling £5m incl investor Northern Gritstone |
2023-09-25 |
| Crucible Therapeutics–SEVERAL: investment, 202309 financing round £5m from Northern Gritstone + Argobio Studio |
2023-09-25 |
| Pepceuticals–Biosynth: investment, 202309 acquisition of Pepceuticals Ltd by Biosynth |
2023-09-25 |
| BenevolentAI–FTI Consulting: public relations, 202309 service existent by FTI Consulting |
2023-09-20 |
| Merck (DE)–BenevolentAI: AI-based drug discovery, 202309– strategic collab up to $594m plus royalties incl low 2-digit-$m upfront |
2023-09-20 |
| Merck (DE)–Exscientia: AI-based drug discovery, 202309– collab $20m upfront + $674m milestones plus royalties |
2023-09-20 |
| Broken String Biosciences–Heran Partners: investment, 202309 financing round Series A totalling $15m incl new + co-investor Heran Partners |
2023-09-18 |
| Broken String Biosciences–Holtzbrinck: investment, 202309 financing round Series A totalling $15m incl existing + co-investor DvH Ventures |
2023-09-18 |
| Broken String Biosciences–Illumina: investment, 202309 financing round Series A totalling $15m incl new + co-lead investor Illumina Ventures |
2023-09-18 |
| Broken String Biosciences–Mérieux: investment, 202309 financing round Series A totalling $15m incl new + co-lead investor Mérieux Equity Partners |
2023-09-18 |
| Broken String Biosciences–SEVERAL: investment, 202309 financing round Series A $15m co-led by Illumina Ventures + Mérieux Equity Partners |
2023-09-18 |
| Broken String Biosciences–Tencent: investment, 202309 financing round Series A totalling $15m incl existing + co-investor Tencent |
2023-09-18 |
| Broken String Biosciences–Zyme Communications: public relations, 202309 service existent by Zyme |
2023-09-18 |
| Bastion Therapeutics–SEVERAL: investment, 202309 seed financing round $840k led by NG Bio |
2023-09-12 |
| Consilium–ICR: investment, 202309 acquisition of Consilium Strategic Communications by ICR |
2023-09-12 |
| Kuano–SEVERAL: investment, 202309 seed financing round £1.8m led by Mercia Ventures |
2023-09-12 |
| BioPharmics–Optibrium: investment, 202308 acquisition of BioPharmics LLC by Optibrium |
2023-08-31 |
| Intellegens–United Kingdom (govt): grant, 202308– 2y Innovate UK grant £1.6m to apply machine learning to manufacture of oligo drugs with CPI |
2023-08-30 |
| Intellegens–Zyme Communications: public relations, 202308 service existent by Zyme |
2023-08-30 |
| Abcam–Danaher: investment, 202308– acquisition $24/share in cash = enterprise value $5.7b incl assumed indebtedness + net of acquired cash |
2023-08-28 |
| Bit Bio–Synthego: gene editing, 202308– collab expansion applying gene editing to otpi-ox technology to engineer human cells for cell therapies |
2023-08-24 |
| Lindus Health–SEVERAL: investment, 202308 financing round Series A $18m led by Creandum |
2023-08-16 |
| NuChem Sciences–Sygnature Discovery: investment, acquisition of NuChem Sciences by Sygnature Discovery |
2023-07-31 |
| NK:IO–SEVERAL: investment, 202307 seed financing round extension £1.2m bringing total seed equity funding to £3.2m |
2023-07-25 |
| NK:IO–Zyme Communications: public relations, 202307 service existent by Zyme |
2023-07-25 |
| Crescendo Biologics–Andera Partners: investment, 202307 financing round totalling $32m incl existing investor Andera Partners |
2023-07-24 |
| Crescendo Biologics–BioNTech: investment, 202307 financing round totalling $32m incl existing investor BioNTech |
2023-07-24 |
| Crescendo Biologics–IP Group: investment, 202307 financing round totalling $32m incl existing investor IP Group |
2023-07-24 |
| Crescendo Biologics–Kreos Capital: investment, 202307 financing round totalling $32m incl new investor Kreos Capital |
2023-07-24 |
| Crescendo Biologics–Quan Capital: investment, 202307 financing round totalling $32m incl existing investor Quan Capital |
2023-07-24 |
| Crescendo Biologics–SEVERAL: investment, 202307 financing round $32m with new investor Kreos Capital + all major existing investors |
2023-07-24 |
| Crescendo Biologics–Sofinnova: investment, 202307 financing round totalling $32m incl existing investor Sofinnova Partners |
2023-07-24 |
| Crescendo Biologics–Takeda: investment, 202307 financing round totalling $32m incl existing investor Takeda |
2023-07-24 |
| Bicycle Therapeutics–SEVERAL: investment, 202307 public offering $200m+$30m with 6.1m+1.4m ADSs + non-voting ordinary shares at $21.25 each |
2023-07-12 |
| Tenpoint Therapeutics–F-Prime: investment, 202307 financing round Series A totalling $70m incl existing + co-lead investor F-Prime Capital |
2023-07-12 |
| Tenpoint Therapeutics–Fidelity: investment, 202307 financing round Series A totalling $70m incl existing + co-investor Eight Roads |
2023-07-12 |
| Tenpoint Therapeutics–Qiming: investment, 202307 financing round Series A totalling $70m incl existing + co-investor Qiming Venture Partners USA |
2023-07-12 |
| Tenpoint Therapeutics–SEVERAL: investment, 202307 financing round Series A $70m led by F-Prime Capital + Sofinnova Partners + British Patient Capital |
2023-07-12 |
| Tenpoint Therapeutics–Sofinnova: investment, 202307 financing round Series A totalling $70m incl existing + co-lead investor Sofinnova Partners |
2023-07-12 |
| Tenpoint Therapeutics–United Kingdom (govt): investment, 202307 financing round Series A totalling $70m incl new + co-lead investor BPC |
2023-07-12 |
| Tenpoint Therapeutics–Univ College London: investment, 202307 financing round Series A totalling $70m incl existing + co-investor UCL Technology Fund |
2023-07-12 |
| NK:IO–United Kingdom (govt): cell therapy manufacturing, 202307– collab developm manufacturing process for cell therapies with CGT Catapult |
2023-07-11 |
| NK:IO–United Kingdom (govt): grant, 202307– Innovate UK grant £1.6m from New Cancer Therapeutics programme |
2023-07-11 |
| Lario Therapeutics–Golgi Neurosciences: investment, 202307 existent investment at time of spin-off of Golgi Neurosciences from Axxam |
2023-07-05 |
| Camena Bioscience–Mercia: investment, 202307 financing round Series A totalling $10m incl lead investor Mercia |
2023-07-03 |
| Camena Bioscience–SEVERAL: investment, 202307 financing round Series A $10m led by Mercia |
2023-07-03 |
| Camena Bioscience–Zyme Communications: public relations, 202307 service existent by Zyme |
2023-07-03 |
| MoonLake–Consilium: public relations, 202306 service existent by Consilium Strategic Communications |
2023-06-28 |
| Astraveus–Optimum Strategic Communications: public relations, 202306 service existent by Optimum |
2023-06-27 |
| AstraZeneca–SandboxAQ: AI-based drug discovery, 202306 collab existent disclosed of AZ with AQBioSim |
2023-06-22 |
| AstraZeneca–Quell Therapeutics: T cell therapy, 202306– collab developm $85m incl equity investment + >$2b milstones + royalties Tregs for T1D + IBD |
2023-06-09 |
| Quell Therapeutics–AstraZeneca: Investment, 202306 equity investment €na by AstraZeneca as part of collaboration |
2023-06-09 |
| Axol Bioscience–StrataStem: drug development technology, 202306– collab excl combining patient samples with iPSC technology for Alzheimer RnD |
2023-06-07 |
| OntoChem–Holtzbrinck: investment, 202306 acquisition 100% of OntoChem by Digital Science |
2023-06-07 |
| Theragnostics–Ariceum Therapeutics: investment, 202306 acquisition 100% of Theragnostics Ltd for $2.5m cash upfront plus $41.5m milestones |
2023-06-01 |
| eXmoor Pharma–Kineticos: investment, 202305 financing round Series A totalling $35m incl new investor Kineticos Ventures |
2023-05-30 |
| eXmoor Pharma–MVM: investment, 202305 financing round Series A totalling $35m incl existing investor MVM Partners |
2023-05-30 |
| eXmoor Pharma–SEVERAL: investment, 202305 financing round Series A $35m from Kineticos Ventures + MVM Partners |
2023-05-30 |
| Michor Consulting–QbD Group: investment, 202305 acquisition of Michor Consulting by QbD Group |
2023-05-25 |
| Renegade Therapeutics–F2 Ventures: investment, 202305 financing round Series A totalling $300m incl co-lead investor F2 Ventures |
2023-05-23 |
| Renegade Therapeutics–SEVERAL: investment, 202305 financing round Series A $300m led by MPM BioImpact + F2 Ventures |
2023-05-23 |
| Oncimmune–Freenome: investment, 202305 acquisition of Oncimmune Ltd by Freenome |
2023-05-22 |
| Dualyx–Consilium: public relations, 202305 service existent by Consilium Strategic Communications |
2023-05-15 |
| Dualyx–Fountain Healthcare Partners: investment, 202305 financing round Series A totalling €40m incl new + co-lead investor Fountain HP |
2023-05-15 |
| Dualyx–SEVERAL: investment, 202305 financing round Series A €40m co-led by Fountain Heathcare Partners + Forbion + Andera Partners |
2023-05-15 |
| Nido Biosciences–SEVERAL: investment, 202305c financing round Series B bringing total from seed + Series A + Series B to $109m |
2023-05-15 |
![[LSUK] Life-Sciences-UK.com - The UK Life Sciences Web Portal](/images/basics/lsuk-life-sciences-uk-portal-logo.svg){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
